Turn Therapeutics TTRX
NASDAQ TTRX
$9.80 -0.27 (-2.68%)
As of: Sep 4, 2026 · 3:59 PM EDT

Turn Therapeutics (TTRX) Non-Current Debt (2026)

Turn Therapeutics (TTRX) posted quarterly Non-Current Debt of $5.9 million for Q1 2026.

Analysis

Turn Therapeutics (TTRX) Non-Current Debt (2026) Analysis & Trends

Turn Therapeutics' Non-Current Debt history runs 1 years deep, the most recent figure standing at $5.9 million for Q1 2026.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Debt (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 1.99 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 591.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn - -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 882.16 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn -
8 Royalty Pharma 28.45 Bn 27.61 Bn - 8.96 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 546.77 Mn
10 Turn Therapeutics 302.05 Mn 302.05 Mn - 6.06 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 6.06 Mn
Mar 31, 2026 5.94 Mn